mainly used Next-Generation Sequencing technology and optimized algorithms to explore the relationship between bTMB and TMB in tumor tissue, indicating that bTMB can be used as an efficacy prediction biomarker of anti-PD-1/PD-L1 immunotherapy in NSCLC (60). This evidence concerns the gene CD274 and neoplasm.